Comment on: The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy
Dear Editor,
STAT+: GLP-1 reduced migraine frequency by nearly half, in a pilot study
GLP-1 drugs could treat more than just diabetes and obesity. They may also reduce migraine frequency. That is according to the findings of a study presented on Friday at the European Academy of Neurology congress. The pilot study found that GLP-1 agonists reduced monthly migraine days by almost half. The authors hypothesized that the drug […]
GLP-1 Drugs Can Be Used First for Weight Loss, Says American College of Cardiology
(MedPage Today) — The American College of Cardiology (ACC) gave popular obesity medications equal standing with diet and exercise as a first-line strategy for weight management. In new concise clinical guidance, the ACC promoted current-generation…
Likelihood of Psych Disorders Lower With Weight-Loss Surgery Versus GLP-1 RAs
FRIDAY, June 20, 2025 — People undergoing metabolic and bariatric surgery (MBS) are less likely to develop psychiatric disorders than those treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a study presented the…
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
FRIDAY, June 20, 2025 — For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and cardiovascular event risks, according to a study published online June 17 in…
Reply to Comment on The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy
We would like to thank Dr. Hsu, Dr. Lin, and colleagues for their thoughtful commentary on our work evaluating the impact of semaglutide and other GLP-1RAs on the risk of NAION,1 and for their ongoing contributions to this important and evolving area of research.
A selective and augmentable FFAR2 signal circuitry programs a butyrate-induced cellular identity of enteroendocrine L-cells
Activation of free fatty acid receptor 2 (FFAR2) on enteroendocrine L-cells mediates secretion of glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), key regulators of central appetite control with therapeutic relevance to obesity. Here, we show that butyrate, a metabolite derived from fermentation of dietary fibre and an FFAR2 agonist, stimulates a PYY-biased profile in […]
GLP-1 drugs and eye health risks: A new watchlist for diabetes patients
(NaturalNews) GLP-1 drugs like Ozempic and Wegovy double the risk of neovascular age-related macular degeneration (wet AMD) in diabetes patients over three year…
4 GLP-1 updates on costs, access
GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024. A separate report found that among nonspecialty medications, there was a 6.3% increase in net cost from 2023 to 2024. Excluding GLP-1s, the increase would have been 3.5%. Denmark-based drugmaker […]
ADA (American Diabetes Association) June 20-23 Obesity Medicines – Other Posters and Talks
🧪 NA‑931 (Bioglutide™) – Biomed Industries, Inc.Presentation (Oral):Title: “Phase 2 Clinical Trials of NA‑931, an Oral Novel Quadruple IGF‑1, GLP‑1, GIP, and Glucagon Receptor Agonist, Reduces Body Weight Without Muscle Loss.”Presenter: Dr. Lloyd L. Tran (CEO)Date & Time: June 20, 2025 – oral session (specific time TBD at conference)Poster:Title: “Association Between Alzheimer’s Disease (AD) and Obesity: Clinical Trial […]